Valuation: Arcturus Therapeutics Holdings Inc.

Market Cap 241M 218M 202M 182M 343M 22.72B 356M 2.43B 962M 12.14B 904M 885M 38.52B P/E 2026 *
-2.9x
P/E 2027 * -2.44x
Enterprise Value 77.06M 69.83M 64.59M 58.27M 110M 7.27B 114M 776M 308M 3.88B 289M 283M 12.32B EV / Sales 2026 *
2.75x
EV / Sales 2027 * 7.51x
Free-Float
92.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.95%
1 week-19.23%
Current month-24.21%
1 month-25.82%
3 months+1.58%
6 months+11.91%
Current year+36.38%
1 week 8.12
Extreme 8.12
10.03
1 month 8.12
Extreme 8.12
12.44
Current year 5.5
Extreme 5.5
17.96
1 year 5.5
Extreme 5.5
17.96
3 years 5.5
Extreme 5.5
45
5 years 5.5
Extreme 5.5
48.75
10 years 4.11
Extreme 4.11
129.71
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-28
Director of Finance/CFO 71 2026-04-30
Chief Tech/Sci/R&D Officer 65 2025-11-30
Director TitleAgeSince
Chairman 84 2018-05-26
Director/Board Member 67 2018-05-26
Director/Board Member 67 2018-05-26
Date Insider Type Main position Quantity % Market Cap. Importance
5/1/26 Free

Chief Financial Officer

100,000 0.3683%
12/17/25 Free

Controller/Auditor

10,000 0.0368%
12/17/25 Free

General Counsel

54,000 0.1989%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%-19.23%+14.99%-62.88% 241M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.23%+3.14%+11.11%+95.64% 60.62B
+1.37%+2.34%+25.10%+91.00% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+3.20%-2.68%+80.36%+62.25% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average +0.10%-1.88%+35.12%+153.62% 41B
Weighted average by Cap. -0.10%+0.19%+37.07%+153.16%

Financials

2026 *2027 *
Net sales 28.01M 25.38M 23.47M 21.18M 39.91M 2.64B 41.32M 282M 112M 1.41B 105M 103M 4.48B 32.1M 29.09M 26.9M 24.27M 45.74M 3.03B 47.36M 323M 128M 1.62B 120M 118M 5.13B
Net income -81.94M -74.25M -68.68M -61.97M -117M -7.73B -121M -825M -327M -4.13B -307M -301M -13.1B -108M -98.13M -90.77M -81.9M -154M -10.21B -160M -1.09B -432M -5.45B -406M -398M -17.31B
Net Debt -164M -149M -137M -124M -234M -15.45B -242M -1.65B -654M -8.26B -615M -602M -26.2B -
Projected Income Statement - Annual - Arcturus Therapeutics Holdings Inc.
Logo Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Employees
109
Date Price Change Volume
26-11-13 US$8.360 -0.95% 377,139
26-11-12 US$8.440 -9.34% 430,325
26-11-11 US$9.310 -0.85% 443,226
26-11-10 US$9.390 -1.05% 851,959
26-11-09 US$9.490 -8.31% 915,689
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Arcturus Therapeutics Holdings Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
8.360USD
Average target price
23.80USD
Spread / Average Target
+184.69%
  1. Stock Market
  2. Stocks
  3. ARCT Stock